MDisrupt : the world’s first medical diligence company for the HealthTech industry

August 23, 2019



Healthtech is one of the fastest growing industries. Investors and entrepreneurs alike are united in their desire to disrupt medicine. Yet, many healthtech companies struggle to bring promising products to widespread market adoption. The data and proof points for health products are much higher than for typical consumer products—but there is a clear path for bringing healthtech products to market. MDisrupt can get you there faster and more responsibly.


Uniting the healthtech and healthcare industries


Our network consists of some of the most experienced people from the scientific, medical, regulatory, and commercial sectors of health care. We call them the MDisruptors. We all share a common desire to see the products that can have the biggest impact on patient care make it to market quickly and responsibly.


We believe the best way to do this is by applying medical diligence—a process that assesses a product’s clinical and commercial viability in a healthcare setting.


By uniting the innovators and investors from healthtech industry with our team of experienced MDisruptors, and applying medical diligence, we can get there faster together.


MDisrupt Process



MDisrupt hypotheses


1) Healthtech entrepreneurs need to find the balance between "go fast and break things" and "first do no harm." If they understood the formula for healthcare market adoption earlier, they could accelerate their path to market.


2) Investors in healthtech need better ways to assess whether or not a healthtech company can successfully capture sufficient market adoption in the expected timeframe.


3) Organizations such as employers, health systems, and commercial retailers who are being approached by healthtech companies need an objective way to assess the clinical viability of health products before they adopt them


Source :


Share on Facebook
Share on Twitter
Please reload

Please reload